Oxford Technology & Innovations EIS Fund (OTIF) invests £230k into University of Oxford spinout company Oxford Endovascular Ltd
- Oxford Endovascular Ltd is commercialising OxiFlow™, a novel blood flow diversion device (‘stent’) for treating Intracranial Aneurysms (ICAs).
- OTIF’s investment was advised by Oxford Investment Consultants LLP and was part of a $10m Series A funding round led by Vulpes Investment Management, a Singapore-based life sciences investor.
- This is the second OTIF investment in Oxford Endovascular to date, bringing total funds invested by the fund in the Company to £500k.
Webinar recording: A Celebration of British Innovation and New Technologies hosted by OIC and Rathbones
We recently held the second webinar in our series of two events celebrating British innovation and new technologies held in conjunction with our friends at Rathbone Investment Management.
OIC portfolio company Oxehealth has secured financial commitments totalling £10m, which will be delivered in two rounds across 2021 and 2022.
The two rounds have been underwritten by existing shareholders, which included a commitment from the Oxford Technology & Innovations EIS Fund (OTIF) advised by OIC.
SpyBiotech appointments of Dan Menichella as Non-Executive Director and Dr Norman Begg as Scientific Advisor
OIC investee company SpyBiotech, which is developing a novel vaccine platform technology targeting infectious diseases, cancer and chronic diseases, has appointed Dan Menichella as an independent, non-executive director and Norman Begg as a scientific advisor.